One of the main advantages of targeting PSMA is its specificity. Since PSMA is predominantly expressed on prostate cancer cells, therapies targeting this protein are more likely to attack the cancer cells while sparing normal cells. This specificity reduces side effects and increases the efficacy of the treatment. Additionally, PSMA-targeted therapies can be combined with other treatments to enhance overall outcomes.
